Aldeyra plans reproxalap NDA resubmission for dry eye disease in H2 2024

Aldeyra Therapeutics, Inc.

Dry eye chamber trial to start H1 2024; NDA resubmission expected H2 2024 if positive.
FDA review period expected to be six months for potential resubmission.
Cash $142.8M as of Dec 31, 2023; projected to fund operations beyond 2026.
Primary endpoint: ocular discomfort; trial design from four prior reproxalap chamber trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.